Skip to main navigation

Corporate Menu & Investor Relations

Contact Patients

Mission Leadership Community

The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications

Overview TC-210 TC-110 Pipeline

Press Releases In the News Awards

Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs

Careers

Corporate Menu & Investor Relations

About Us Mission Leadership Community Technology The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications Programs Overview TC-210 TC-110 Pipeline News Press Releases In the News Awards Investors Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs Careers Careers Contact Patients

Presentations

Presentations

Corporate Presentation - January

TCR² Corporate Presentation - January 2021 4.1 MB

Interim Clinical Data from Gavo cel (TC 210) Patients

Interim Clinical Data from Gavo cel (TC 210) Patients 1.4 MB

TC-210 Phase 1 Interim Data

TC-210 Phase 1 Interim Data 5.3 MB

June 2020 - AACR Virtual Annual Meeting II

A Chimeric PD1-CD28 Switch Receptor Enhances the Activity of TRuC-T Cells 2.7 MB

Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuC™) T Cells 11.3 MB

February 2020 - Keystone Symposia

Engineering Off-the-Shelf T Cell Receptor Fusion Construct (TRuC^TM) T Cells 5.1 MB

April 2019 - AACR

Preclinical Evaluation of TC-110: CD19-Specific T Cell Receptor (TCR) Fusion Construct (TRuC^TM) T Cells for the Treatment of Hematologic Malignancy 4.5 MB

Preclinical Evaluation of TC-210: A Mesothelin-Specific T Cell Receptor (TCR) Fusion Construct (TRuC^TM) T Cells for the Treatment of Solid Tumors 7.2 MB

Tools

Print Page
RSS Feeds
Email Alerts
Contact IR

100 Binney Street, Suite 710
Cambridge, MA 02142
617.949.5200

Corporate Menu & Investor Relations

About Us
Technology
Programs
News
Investors
Careers
Contact
Patients